Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2 trial of TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder. The 6-week, randomized, double-blind, placebo-controlled study plans to enroll approximately 360 patients at about 30 U.S. sites, with a primary endpoint of change from baseline in the MADRS depression score at Week 6 and secondary measures including global impression, anxiety, and sleep quality. TNX-102 SL, a sublingual cyclobenzaprine tablet, is already FDA-approved as TONMYA for fibromyalgia in adults, and Tonix holds multiple U.S. patents expected to provide market exclusivity for TNX-102 SL until 2034, with method-of-use applications that could extend to 2044.
Tonix Pharmaceuticals Holding Corp. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 890,366 shares of Common Stock, representing 5.6% of the class, with the cover date 06/09/2026.
A Joint Filing Agreement dated June 12, 2026 is attached; the filing lists the filers' principal address as 399 Park Avenue, New York.
Tonix Pharmaceuticals Holding Corp. director Carolyn E. Taylor reported an open-market purchase of common stock. She bought 1,415 shares of Tonix common stock at an average price of $10.55 per share. After this transaction, she directly owns 1,833 shares of Tonix common stock.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell reported an open-market purchase of 5,000 common shares. The shares were bought on June 8, 2026 at a weighted average price of $11.65 per share, with individual trade prices ranging from $11.63 to $11.65. Following this transaction, Stillwell directly holds 5,000 Tonix common shares.
Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman reported an open-market purchase of common stock. On June 9, 2026, he bought 5,000 shares at a weighted average price of $11.79 per share in a series of trades priced between $11.735 and $11.883.
Following this purchase, Lederman directly owns 9,005 common shares. He also has indirect ownership of 1 share through Lederman & Co. and 20,001 shares through an IRA account, where he may be deemed a control person of the Lederman & Co. entity.
Tonix Pharmaceuticals entered an agreement with a second leading group purchasing organization effective June 1, 2026, expanding commercial payer coverage for TONMYA, its FDA-approved fibromyalgia treatment for adults. The new contract adds access for approximately 17 million U.S. commercially insured individuals with standard utilization management criteria.
Combined with a prior GPO deal, TONMYA now has commercial coverage for about 52 million U.S. lives, representing roughly 29% of an estimated 177 million commercial lives. TONMYA is also available under Medicaid in most states, covering approximately 75 million beneficiaries, and Tonix continues discussions with Medicare while supporting patients through its TONMYA Together savings program.
Tonix Pharmaceuticals Holding Corp. reported that Phase 1 clinical data for its investigational monoclonal antibody TNX-1500 were published in the Journal of Clinical Immunology. In a first-in-human study of 26 healthy adults, single intravenous doses of 3, 10, or 30 mg/kg were generally well tolerated, with no serious adverse events and only mild, transient aphthous ulcers deemed possibly related to TNX-1500.
TNX-1500 significantly suppressed T cell-dependent antibody responses to the KLH antigen, blocking primary responses at all doses and secondary responses at 10 and 30 mg/kg, with about a 70% reduction at 3 mg/kg versus placebo. Pharmacokinetic data showed dose-proportional exposure and terminal half-lives around 34–38 days, supporting monthly dosing. Tonix highlighted that a Phase 2 investigator-initiated study in kidney transplant recipients at Massachusetts General Hospital is expected to begin in the second half of 2026, pending FDA clearance of the IND.
Tonix Pharmaceuticals Holding Corp. ownership update: Point72 group reports beneficial ownership of 1,100,964 shares of Common Stock, representing 6.9% of the class as of the close of business on May 14, 2026. The filing attributes shared voting and dispositive power across Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.
A footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 125,414 shares (representing 0.9% as of that date). The statement clarifies that the reporting persons directly own no shares and that Point72 Associates holds the referenced securities.
Tonix Pharmaceuticals reported Phase 1 results for TNX-4800, an investigational long-acting monoclonal antibody designed to prevent Lyme disease. In 44 healthy volunteers, single subcutaneous doses showed a favorable safety profile, mostly mild injection-site reactions, and dose‑proportional pharmacokinetics with a mean half‑life of about 62–69 days. Serum levels were detectable within two days and remained quantifiable for up to 12 months in most participants, with exposure at the highest 10 mg/kg dose under 17% of peak levels seen in rat toxicology. Nonclinical primate data support protective serum thresholds, and modeling underpins a two‑dose regimen. Tonix plans an adaptive Phase 2 field study in 2027, pending FDA agreement, while highlighting approximately $185.5 million in cash and no debt as of March 31, 2026.
Tonix Pharmaceuticals Holding Corp. reporting persons Sirenia Capital Management and Alex Silverstein disclose beneficial ownership of 1,297,470 shares of common stock, representing 8.8% of the class on an as‑converted basis. The percentage "assumes the exercise of the warrants" held by the Sirenia Fund.
The filing cites 14,205,401 shares outstanding as of March 27, 2026 from the issuer's proxy statement and notes that 615,025 shares are issuable upon exercise of warrants included in the reported total.